Barbara Burtness
Chief Translational Research Officer · Yale Cancer Center
Credentials: · · · · ·
History
- Present
Head and Neck Cancers/Sarcoma Division · Yale Cancer Center
- Present
Developmental Therapeutics · Yale Cancer Center
- Present
Head and Neck Cancers/Sarcoma Division · Yale-New Haven Hospital
- 1986–1987
- 1978–1982
Research
Head and neck squamous cell carcinoma
Review · Nature Reviews Disease Primers · 2020 · 3,449 citations
The Lancet · 2019 · First of 25 authors · Corresponding · 2,744 citations
The Lancet Oncology · 2016 · 1,435 citations
42 papers · 1 as a fellow
- JR
33 papers
31 papers
28 papers
27 papers
- AF
22 papers
22 papers
20 papers · 10 as a resident
Grants
- 2020–2031
Yale-UNC Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck Cancer
National Institute of Dental and Craniofacial Research · P50
Contact PI · $1.8M · Yale University
- 1997–2029
- 2020–2026
Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck Cancer
National Institute of Dental and Craniofacial Research · P50
Contact PI · $11.8M · Yale University
- 1997–1998
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $84.8K · Yale University
Clinical trials
- 2023–2027
Principal investigator · Recruiting · Phase 2
IO Biotech
- 2023–2028
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
Principal investigator · Recruiting · Phase 2
Barbara Burtness
- 2016–2020
Pembrolizumab in HNSCC With Residual Disease After Radiation
Principal investigator · Terminated · Phase 2
Yale University
- 2015–2019